Rationale: Transforming growth factor (TGF)-beta was linked to abnormal vessel function and can mediate impairment of endothelial angiogenic responses. Its effect on microRNAs and downstream targets in this context is not known.
INTRODUCTION
Transforming growth factor-beta (TGF-beta) is an important cytokine in vascular homeostasis, plays crucial roles in vascular development and in endothelial cells generally blocks angiogenesis by inhibiting endothelial cell proliferation, tube formation and migration [1] [2] [3] [4] [5] . Clinically, high TGF-beta levels have been linked to impaired collateral function in patients with coronary artery disease 6 or presence of peripheral stenotic atherosclerosis 7 and increased plasma levels of TGF-beta are found to reflect pathological left ventricular remodeling 8 . Mechanistically, the effects of TGF-beta in endothelial cells are mainly mediated via specific Smad proteins leading to inhibition of angiogenic responses of endothelial cells 1 . However, whether also small non-coding regulatory RNAs are involved in its angiogenic inhibitory effects in endothelial cells is less clear. We recently identified TGF-beta to drive endothelial-to-
MiRNA-30a-3p targets the Methyl CpG Binding Protein 2 (MeCP2) in endothelial cells.
We next searched for miR-30a-3p targets in endothelial cells. Bioinformatic prediction tools identified Methyl-CpG-Binding-Protein 2 (MeCP2) to be a potential well conserved target for miR-30a-3p (Fig. 1c) . We employed a luciferase gene reporter assay using a pMIR-REPORT vector containing 329 bp of MeCP2 3'UTR encompassing the potential miR-30a-3p target sequence. Co-transfection with pre-miR30a-3p led to a significant reduction in luciferase activity, whereas miR30a-3p inhibition increased luciferase activity (Fig. 1d) . Further, transfection of endothelial cells with miR-30a-3p precursors significantly reduced MeCP2 protein levels, whereas anti-miR-30a-3p transfection elevated MeCP2 levels (Fig. 1e) . Consistent with this, TGF-beta treatment of endothelial cells (which resulted in a strong decrease in miR-30a-3p levels) led to an increase in MeCP2 transcript and protein levels. Importantly, TGF-beta induced elevation of MeCP2 expression was normalised by miR-30a-3p overexpression (Fig.  1f , Online Figure III g ). These experiments identified MeCP2 as a direct miR-30a-3p target in endothelial cells.
MeCP2-mediated impairment of endothelial migration and tube formation.
We next aimed to characterize potential functions of the miR-30a-3p target MeCP2 in endothelial cells. First, we constructed a MeCP2-carrying lentivirus to transduce endothelial cells (Online Figure To better understand the molecular mechanisms of MeCP2-mediated effects on endothelial cells, we performed further global transcriptome analysis by microarray analysis comparing the mRNA-expression patterns in control (GFP-vector) and MeCP2-transduced cells. We found MeCP2 overexpression to deregulate 1268 transcripts (fold change >2, Online Table II) . We next focused on differently regulated genes described to be of critical importance for endothelial cell biology (Fig. 2b ) and identified the class III histone deacetylase sirtuin 1 (SIRT1), which is crucial for many endothelial cell functions 16, 17 to be strongly down-regulated upon MeCP2 over-expression. This was confirmed by real-time PCR and Western blotting (Fig. 2c,d ). In contrast, MeCP2 knockdown led to an increase of SIRT1 suggesting a direct regulatory mechanism (Online Figure III f). TGF-beta treatment, which increases MeCP2 expression, also resulted in SIRT1 down-regulation (Fig. 2e,f) . Importantly, overexpression of miR-30a-3p in TGF-beta treated endothelial cells restored SIRT1 expression levels indicating that the TGF-betamiR-30a-3p-MeCP2 axis is responsible for SIRT1 regulation (Fig. 2e,f) . We next tested, whether TGFbeta-mediated endothelial cell impairment is MeCP2/Sirt1-dependent.
Endothelial TGF-beta effects are mediated via MeCP2/Sirt1 in vitro and in vivo.
In vitro, TGF-beta mediated repression of endothelial migration and tube formation was rescued by MeCP2 silencing or Sirt1 overexpression ( Fig. 3a,b ; Online Figure IV a,b) . To check the in vivo relevance of MeCP2/Sirt1, we implanted angioreactors in various genetic mouse models to monitor angiogenesis (Fig. 3c) . Addition of TGF-beta in the reactors blunted growth-factor-mediated vascularisation in wild type mice. However, in mice that genetically lack MeCP2 expression specifically in endothelial cells and in mice that over-express Sirt1 (Online Figure IV c,d ) the detrimental effects of TGF-beta on angioreactor-vascularization were strongly attenuated (Fig. 3c) . In line, SIRT1 levels in endothelial cells from MeCP2 null mice were increased (Fig. 3d) . Similarly, ex vivo endothelial sprouting was inhibited when aortic rings from wildtype mice were cultured in the presence of TGF-beta. Again, TGF-beta effects on endothelial sprouting were abrogated in aortic rings from MeCP2 KO mice or Sirt1 TG mice (Online Figure V) . Finally, ex vivo cultured lung-derived microvascular endothelial cells isolated from wildtype, but not MeCP2 KO or Sirt1 TG mice displayed TGF-beta mediated impairment of migration (Fig. 3e) . These results strongly suggest that MeCP2 and SIRT1 play important roles in
FIGURE LEGENDS
Figure 1: TGF-beta mediated regulation of miRNAs and identification of MeCP2 as a direct miR30a-3p target. a) Real-time-PCR-based miRnome screening of endothelial cells, treated with TGFbeta or control. MiRNA-30 family is marked with red dots. Less than 2-fold regulated miRNAs are marked in grey. b) Migratory capacity of endothelial cells treated with TGF-beta, TGF-beta and miR-30a-3p or miR-30a-3p overexpression. c) MiRNA-30a-3p binding to target MeCP2-mRNA (upper) and conservation of the miRNA-30a-3p binding site in MeCP2-mRNA throughout different species. d) Luciferase-activity and e) MeCP2 protein expression in control and pre-miR30a-3p and anti-miR-30a-3p treated endothelial cells. f) Protein expression after TGF-beta and pre-miR-30a-3p-treatment. n=3, *=p<0.05, **=p<0.01, ***=p<0.001, data are mean ± SEM. SIRT1 mRNA (e) and protein (f) expression after TGF-beta treatment or TGF-beta+pre-miR-30a-3p or pre-miR-30a-3p alone overexpression in endothelial cells. n=3-4, *=p<0.05, **=p<0.01, ***=p<0.001. Data are mean ± SEM. 
Novelty and Significance

What Is Known?
 MicroRNAs are short endogenous regulatory RNA molecules that post-transcriptionally regulate gene expression networks and cellular functions.
 Many microRNAs play an important role in angiogenesis and can be used as therapeutic targets.
 Epigenetics is the study of changes in gene expression or cellular phenotypes caused by mechanisms other than changes in the underlying DNA sequence.
What New Information Does This Article Contribute?
 TGFbeta, a cytokine often induced in cardiovascular diseases, leads to the silencing of the miRNA-30 family in endothelial cells.
 miRNA-30a-3p regulates an epigenetic-acting protein leading to impaired angiogenic activity of endothelial cells.
 MiR-30a-3p and its downstream effectors are important players in endothelial actions of TGFbeta and thus potential molecular targets for angiogenic therapies.
MicroRNAs are endogenous master regulators of genetic pathways and regulate angiogenic responses.
Here we show that transforming growth factor beta, a cytokine often increased in cardiovascular diseases, silences the miRNA-30 family in endothelial cells. This leads to the de-repression of an important epigenetic factor. The term "epigenetics" is used to describe changes in gene expression mediated by mechanisms other than underlying DNA changes. Our observation that a microRNA in endothelial cells affects downstream epigenetic pathways leading to impaired angiogenic activityopens new avenues for using miRNAs as epigenetic modifiers to develop of novel vascular therapeutic strategies. 
Supplemental Methods
MicroRNA profiling
MicroRNA profiling was performed to study TGF-beta induced changes in microRNA expression. For this we used the RT-PCR based microRNA profiler system (System Biosciences) that was built upon on miRNAs included in human miRNome Sanger miRBase (version 15) as per manufacturer's instructions. This was done in pooled samples of each n=3 experiments followed by Taqman validation of the miR-30 family members. A miRNA was judged to be "expressed" only when it showed a CT value of <32 and >18.
Microarray mRNA gene expression profiling RNA was isolated via Trifast method and gene expression profiling was performed using Affymetrix GeneChip Human Genome U133 Plus 2.0 Array according to manufacturer instructions. Samples from two independent experiments per group were used for this purpose.
Generation of lentiviral MeCP2 and Sirt1-overexpression vectors
Lentiviral constructs utilized in this study were based on third-generation self-inactivating vectors 1 . For MeCP2 lentivirus, human MeCP2-IRES-dTomato cassette was inserted into these vectors by AgeI and SalI restriction enzyme digestion. For Sirt1-lentivirus production, pLenti-GIII-CMV-hSIRT1-GFP-2A-Puro plasmid was purchased from Applied Biological Materials Inc (Richmond, Canada). Viral vector production was performed by four-plasmid transient transfection as previously described 2 . Briefly, 3.5x10 6 HEK293T cells were seeded 24h prior to transfection in 10 cm dishes and cultured in high-glucose DMEM (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat-inactivated FCS, penicillin-streptomycin and 1 mM L-glutamine. Cells were transfected with 5 µg lentiviral vector, 8 µg pcDNA3.GP.4xCTE (expressing HIV-1 gag/pol), 5 µg pRSV-Rev and 2 µg pMD.G (encoding the VSV glycoprotein) using the calcium phosphate precipitation method in the presence of HEPES buffer and chloroquine. Supernatants were harvested 48h and 72h after transfection, filtered and subsequently concentrated 50-fold by ultracentrifugation. Viral titers determined by flow cytometry were in the range of 1-5x10 7 viral particles/ml. Target cell transduction was performed in the presence of 8µg/ml protamine sulfate.
Luciferase reporter assays
MeCP2 was identified as a putative target of miR-30a-3p using PicTar database (http://pictar.mdc-berlin.de/). Targeting was confirmed by luciferase reporter assay in HEK293 cells. A 329 nt fragment in MeCP2 3'UTR encompassing putative target sequence was gene-synthesized and cloned into pMIR-REPORT vector (Ambion) between SpeI and HindIII sites by MWG Operon. Luciferase reporter (20ng/well) was co-transfected along with pre-or anti-miR-30a-3p (100nM) and beta-galactosidase-expressing plasmid (10ng/well) into HEK293 cells using lipofectamine (Invitrogen) in 48-well plates. Luciferase and betagalactosidase enzyme activity was measured after 48 h of transfection and luciferase values were normalized to beta-galactosidase readings.
Protein expression
Cells were lysed in a non-denaturing lysis buffer (Cell Signaling Technology) by repeated freeze-thaw cycles or sonification for 15s and separated on 10% polyacrylamide gel, electroblotted on polyvinylidene fluoride membrane. Membranes were blocked and incubated with primary antibodies overnight at 4°C and then incubated with a horseradish peroxidaselabelled secondary antibody (Cell Signaling Technology) followed by enhanced chemiluminescence-based detection (GE Healthcare). Antibodies for endothelial nitric oxide synthase (eNOS) (610296) was purchased from BD-pharmingen and PECAM-1 (ab24590), MeCP2 (ab2828), SIRT1 (ab75435), and GAPDH (ab8245) were purchased from Abcam.
Real-time polymerase chain reaction RNA was isolated per manufacturer's instructions by using Trifast reagent. MiRNAs and RNU6b expression was studied by specific TaqMan assays (Applied Biosystems). Messenger RNA expression of GAPDH, MeCP2 and SIRT1 was analyzed by SYBR Green method using the following primers: GAPDH (F) 5'CCA GGC GCC CAA TAC G3', (R) 5'CCA CAT CGC TCA GAC AC CAT3'; MeCP2 (F) 5'GC TCC AAC AGG ATT CCA TGG T3', (R) 5'GAG GTC CTG GTC TTC TGA CTT TTC3'; SIRT1 (F) 5'TCG CAA CTA TAC CCA GAA CAT AGA CA3', (R) 5'CTG TTG CAA AGG AAC CAT GAC A3'.
Endothelial tube formation experiments
Endothelial cells were treated with TGF-beta and/or pre-miR-30a-3p or anti-miR-30a-3p for 72h. In another set of experiments, endothelial cells were transduced with MeCP2, Sirt1 or GFP (control) viruses or transfected with MeCP2 siRNA. At the end of the treatment/transfection, cells were pelleted, resuspended in EGM2 and added to Matrigel (BD Biosciences) coated chamber slides. Images were captured six hours after seeding and total tube length was measured using NIS-elements BR (Nikon) software.
Boyden-chamber/ scratch-wound migration For Boyden-chamber migration, endothelial cells (HUVECs or primary microvascular endothelial cells from mouse lungs; method see below) were treated with TGF-beta and/or pre-miR-30a-3p or anti-miR-30a-3p for 72 h. In another set of experiments, endothelial cells were transduced with MeCP2, Sirt1 or GFP (control) viruses or transfected with MeCP2 siRNA. At the end of the treatment/transfection, cells were incubated for two hours with DAPI, pelleted and resuspended in EBM2 with 0.1% BSA and seeded on fibronectin coated trans-well inserts (BD Biosciences). Inserts were placed in wells containing chemoattractants (VEGF 5ng/ml, SDF100ng/ml). Images were captured after six hours and number of migrated cells was counted using NIS-elements BR software. For Scratch-wound migration, endothelial cells were treated as described above and allowed to grow until confluency. Then, the confluent cell layer was scratched with a 100 μl pipet tip. Afterwards, medium was changed after washing with PBS. Newly added medium contained mitomycin in order to prevent effects of cell proliferation. Images were captured at 0 and 6h and migration index i was calculated.
Genome methylation assay
Genomic DNA was isolated via DNeasy Blood & Tissue Kit (Qiagen), and genome methylation was analysed using an ELISA-based assay (MethylFlash, Epigentek, NY) per manufacturer's instructions.
Bisulfite Sequencing based SIRT1 promoter methylation assay
For promoter methylation analysis of SIRT1, genomic DNA was isolated using the GenElute Mammalian gDNA Kit (Sigma-Aldrich) and bisulfite converted with the EpiTect Kit (Qiagen). Primers amplifying a CpG island within 3 kb upstream of the start codon of Sirt1 were designed with MethPrimer (http://www.urogene.org/methprimer/index1.html). Nested PCR products were subcloned into pCR2.1 vector with the TopoTA cloning Kit (Invitrogen). Individual colonies were picked, plasmid DNA was purified and DNA was sequenced using M13 primers. Degree of methylated DNA was analyzed with the BiQ Analyzer Software Generation of endothelial-specific MeCP2 deficient mice and use of Sirt-1 transgenic mice To study the role of MeCP2 in TGF-beta mediated endothelial function, we ablated MeCP2 specifically in endothelial cells. Endothelial-specific inactivation of the MeCP2 gene was achieved using the Cre/loxP system. Mice carrying a conditional MeCP2 allele (MeCP2flox) 4 were crossbred with mice expressing Cre recombinase under control of the cadherin 5 promoter (Cdh5Cre ERT2) 5 . Cre activity was induced in adult mice by i.p. administration of 100µl tamoxifen solution (20 mg/ml tamoxifen, Sigma #T5648, dissolved in sunflower oil) per animal on five consecutive days. Tamoxifen-treated Cre-negative littermates served as controls termed "wildtypes" in the present manuscript. Similarly, to study the role of Sirt1 in countering the effects of TGF-beta, we employed a mouse model over-expressing Sirt1 under control of beta-actin (C57BL/6-Actb tm3.1(Sirt1)Npa /J; purchased from the Jackson Laboratory).
Aortic ring assay
Sprouting angiogenesis was studied ex vivo by an aortic ring assay as previously described 6 . Briefly, 70ul of Matrigel containing FGF-2 and VEGF (5 ng/ ml) along with or without TGFbeta (10ng/ml) was coated to a 48-well plate. Aortas were isolated from Wt, endothelialspecific MeCP2 KO and Sirt1 TG mice. Aortic rings were excised from aortas and placed in matrigel coated wells as described above. Aortic rings were covered with additional matrigel and cultured in endothelial specific EGM2 medium containing TGF-beta or BSA for 6 days. Images were acquired on day 6.
Chromatin-immuno precipitation PCR assays
To study a potential association of MeCP2 with the Sirt1 promoter and its modulation after TGF-beta treatment, chromatin-bound MeCP2 was immunoprecipitated using a MeCP2 antibody (Abcam, ab2828) as per manufacturer's instructions followed by quantitative PCR for the Sirt1 promoter. As MeCP2 recruits histone methytransferase activity directed against lysine 9 of histone 3 7 which is linked to gene silencing, we studied if TGF-beta treatment influences presence of a repressive epigenetic chromatin mark i.e, Histone 3 Lysine 9 dimethylation (H3K9me2) on nucleosomes within the Sirt1 promoter. Briefly, nucleosomes carrying H3K9me2 were immuno-precipitated using a specific antibody against H3K9me2 (GAH-8211, SA Biosciences) in control (BSA) or TGF-beta treated endothelial cells followed by investigations about enrichment of Sirt1 promoter by quantitative PCR. Primer sequences used to amplify Sirt1 promoter containing CpG islands were as follows: For -5'GAG ACG GAG TTT CGC TCT TG3'; Rev -5'CCT GAA GTC GGA AGTT CGA G3'.
In vivo angiogenesis angioreactor assay
To study the TGF-beta mediated modulation of angiogenesis in vivo in various genetic mouse models (Wt, endothelial MeCP2-KO or Sirt1-TG) we employed an angioreactor assay. Briefly, silicon tubes with 3mm thickness were filled with matrigel containing 10ng/ml TGF-beta or BSA with or without growth factors (VEGF 50ng/ml, FGF2 250ng/ml). These matrigel containing tubes (angioreactors) were implanted subcutaneously in mice. Tubes were harvested and photographed after 2 weeks to measure vascularisation.
Isolation of microvascular endothelial cells
Microvascular cells were isolated from explanted lungs of wild type, MeCP2-KO and Sirt1-TG mice as follows; single cell suspensions from lungs were obtained using Gentle MACS dissociator (Miltenyi Biotec) and endothelial cells were separated by MACS-based positive selection using MicroBeads coated with CD-31 antibody (Miltenyi Biotec) as per manufacturer's instructions and as described 8 .
Statistical analyses
All experiments (except miRNA and mRNA expression profiling) were performed at least in triplicates and results are presented as average with standard error of the mean (SEM) unless mentioned otherwise. Statistical analysis was performed using Graphpad Prism. Student t-test was used for comparisons between two groups and ANOVA followed by Bonferroni multiple comparison test was used for comparison between more than two groups. A probability value of ≤ 0.05 was considered statistically significant. Online Tables (I,II) microRNA Online Table I : MiRnome-Screen for deregulated microRNAs after TGF-beta treatment, compared to control. Only more than 2-fold deregulated microRNAs are shown. 
Hs 
